Literature DB >> 6821629

Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.

R F Struck, D J Dykes, T H Corbett, W J Suling, M W Trader.   

Abstract

Isophosphoramide mustard was synthesized and was found to demonstrate activity essentially comparable to cyclophosphamide and ifosfamide against L1210 and P388 leukaemia. Lewis lung carcinoma, mammary adenocarcinoma 16/C, ovarian sarcoma M5076, and colon tumour 6A, in mice and Yoshida ascitic sarcoma in rats. At doses less than, or equivalent to, the LD10, isophosphoramide mustard retained high activity against cyclophosphamide-resistant L1210 and P388 leukaemias, but was less active against intracerebrally-implanted P388 leukaemia while cyclophosphamide produced a 4 log10 tumour cell reduction. It was also less active (one log10 lower cell kill) than cyclophosphamide against the B16 melonoma. Metabolism studies on ifosfamide in mice identified isophosphoramide mustard in blood. In addition, unchanged drug, carboxyifosfamide, 4-ketoifosfamide, dechloroethyl cyclophosphamide, dechloroethylifosfamide, and alcoifosfamide were identified. The latter 4 metabolites were also identified in urine from an ifosfamide-treated dog. In a simulated in vitro pharmacokinetic experiment against L1210 leukaemia in which drugs were incubated at various concentrations for various times, both 4-hydroxycyclophosphamide and isophosphoramide mustard exhibited significant cytoxicity at concentration times time values of 100-1000 micrograms X min ml-1, while acrolein was significantly cytotoxic at 10 micrograms X min ml-1. Treatment of mice with drug followed by L1210 cells demonstrated a shorter duration of effective levels of cytotoxic activity for isophosphoramide mustard and phosphoramide mustard in comparison with cyclophosphamide and ifosfamide. Isophosphoramide mustard and 2-chloroethylamine, a potential hydrolysis product of isophosphoramide mustard and carboxyifosfamide, were less mutagenic in the standard Ames test than the 2 corresponding metabolites of cyclophosphamide [phosphoramide mustard and bis(2-chloroethyl)amine].

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6821629      PMCID: PMC2011256          DOI: 10.1038/bjc.1983.2

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.

Authors:  R F Struck; M C Kirk; M H Witt; W R Laster
Journal:  Biomed Mass Spectrom       Date:  1975-02

2.  Synthesis and metabolic behavior of the suggested active species of isophosphamide having cytostatic activity.

Authors:  A Takamizawa; S Matsumoto; T Iwata; Y Tochino; K Katagiri
Journal:  J Med Chem       Date:  1974-11       Impact factor: 7.446

3.  Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite.

Authors:  D L Hill; W R Laster; M C Kirk; S el-Dareer; R F Struck
Journal:  Cancer Res       Date:  1973-05       Impact factor: 12.701

4.  Metabolism of cyclophosphamide by sheep.

Authors:  J E Bakke; V J Feil; C E Fjelstul; E J Thacker
Journal:  J Agric Food Chem       Date:  1972 Mar-Apr       Impact factor: 5.279

5.  Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide.

Authors:  R A Alarcon; J Meienhofer; E Atherton
Journal:  Cancer Res       Date:  1972-11       Impact factor: 12.701

6.  [New nitrogen mustard phosphamide esters and their cytostatic activity].

Authors:  N Brock
Journal:  Laval Med       Date:  1968-10

7.  Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test.

Authors:  B N Ames; J Mccann; E Yamasaki
Journal:  Mutat Res       Date:  1975-12       Impact factor: 2.433

8.  The enzymatic basis of the selective action of cyclophosphamide.

Authors:  P J Cox; B J Phillips; P Thomas
Journal:  Cancer Res       Date:  1975-12       Impact factor: 12.701

9.  Alkylating properties of phosphoramide mustard.

Authors:  M Colvin; R B Brundrett; M N Kan; I Jardine; C Fenselau
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

10.  [Alkylans-alkylandum reactions. 4. 2-chlorethylamine and phosphamide compounds as alkylants].

Authors:  H M Rauen; H Schriewer
Journal:  Arzneimittelforschung       Date:  1971-04
View more
  3 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

2.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.

Authors:  V Gilard; M C Malet-Martino; M de Forni; U Niemeyer; J C Ader; R Martino
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.